Technical Study: Cell Therapeutics Inc., ACADIA Pharmaceuticals Inc., Sarepta Therapeutics Inc., and Medivation Inc.
LONDON, September 25, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
The U.S. equity market closed on a mixed note on Tuesday, September 24, 2013. The S&P 500 and the Dow Jones Industrial Average ended lower, while the NASDAQ Composite posted gains. Shares in the biotechnology industry mostly ended on a higher note, even as the broader market fluctuated between gains and losses. Cell Therapeutics Inc. (NASDAQ: CTIC), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Sarepta Therapeutics Inc. (NASDAQ: SRPT), and Medivation Inc. (NASDAQ: MDVN), were amongst the major movers. AAAResearchReports.com free coverage on CTIC, ACAD, SRPT, and MDVN is available upon registration at:
http://www.aaaresearchreports.com/register/
Shares in Cell Therapeutics Inc. surged 3.56% on Tuesday, extending the gains from the previous trading session. The company's shares fluctuated between $1.58 and $1.77 before ending the day at $1.60. A total of 7.51 million shares were traded, which is above the daily average volume of 1.49 million. The company's shares have rallied 46.79% in the previous three months and 39.13% in the last one month, outperforming the S&P 500 which has gained 7.90% and 2.04% during the respective periods. Moreover, Cell Therapeutics Inc.'s stock is currently trading above its 50-day and 200-day moving averages of $1.13 and $1.22, respectively. Download free technical research on CTIC by signing up at:
http://www.AAAResearchReports.com/CTIC092513.pdf
ACADIA Pharmaceuticals Inc.'s shares rose sharply on Tuesday, even as the broader market finished on a mixed note. The company's shares closed the day 1.30% higher at $24.94 after oscillating between $24.40 and $25.11 during the trading session. A total of 1.12 million shares were traded, which is below the daily average volume of 2.17 million. The company's stock has rallied 42.68% in the last three months and 20.89% in the previous one month, compared to a gain of 7.90% and 2.04% in the S&P 500 during the respective periods. Additionally, ACADIA Pharmaceuticals Inc.'s shares are trading near their 52-week high of $25.50 as well as above their 50-day and 200-day moving averages of $20.88 and $12.68, respectively. Register now and get access to free analysis on ACAD at:
http://www.AAAResearchReports.com/ACAD092513.pdf
Sarepta Therapeutics Inc.'s stock fell by 0.75% on Tuesday, reversing some gains from its rally in the previous trading session. The company's shares oscillated between $46.63 and $48.78 before ending the day at $47.61. A total of 2.69 million shares were traded, which is above the daily average volume of 1.95 million. The company's shares have rallied 29.76% in the previous three trading sessions and 41.49% in the last one month, compared to a loss of 1.45% and a gain of 2.04% in the S&P 500 during the respective periods. Moreover, Sarepta Therapeutics Inc.'s stock is currently trading above its 50-day and 200-day moving averages of $37.12 and $33.41, respectively. Sign up and read our complimentary report on SRPT at:
http://www.AAAResearchReports.com/SRPT092513.pdf
On Tuesday, Medivation Inc.'s stock advanced to close at $57.47, up 0.21% from the previous day's closing price of $57.35. The company's shares oscillated between $56.91 and $57.91 during the trading session. A total of 0.31 million shares were traded, which is below the daily average volume of 0.89 million. The company's shares have rallied 25.10% in the previous three months, outperforming the S&P 500 which has gained 7.90% during the same period. Additionally, Medivation Inc.'s stock is trading above its 50-day and 200-day moving averages of $57.42 and $52.80, respectively. The free report on MDVN can be downloaded by signing up now at:
http://www.AAAResearchReports.com/MDVN092513.pdf
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.AAAresearchreports.com
SOURCE AAA Research Reports
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article